Clustering data with hclust algorithm for (Study ST002124)
(Analysis AN003477)Metabolite | Structure | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 | F13 | F14 | F15 | F16 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[13C, 15N]Glutamic acid, 3TBDMS | ME516630 | 0.01 | 1.31 | 1.06 | 1.22 | 0.03 | 2.76 | 0.56 | 1.63 | 0.02 | 1.61 | 1.11 | 1.42 | 0.01 | 1.20 | 0.99 | 1.06 |
[13C, 15N]Proline, 2TBDMS | ME516638 | 0.01 | 1.33 | 1.09 | 1.21 | 0.02 | 2.27 | 0.73 | 1.57 | 0.02 | 1.51 | 1.14 | 1.22 | 0.01 | 1.38 | 1.20 | 1.30 |
[13C, 15N]Valine, 2TBDMS | ME516642 | 0.02 | 1.60 | 1.08 | 1.16 | 0.02 | 2.24 | 0.75 | 1.37 | 0.02 | 1.62 | 1.13 | 1.16 | 0.02 | 1.57 | 1.14 | 1.10 |
[13C, 15N]Isoleucine, 2TBDMS | ME516633 | 0.02 | 1.56 | 1.18 | 1.39 | 0.02 | 1.95 | 0.61 | 1.13 | 0.02 | 1.62 | 1.18 | 1.41 | 0.01 | 1.43 | 1.12 | 1.37 |
[13C, 15N]Phenylalanine, 2TBDMS | ME516637 | 0.02 | 1.51 | 1.25 | 1.28 | 0.02 | 1.95 | 0.75 | 1.24 | 0.02 | 1.77 | 1.16 | 1.33 | 0.01 | 1.27 | 1.20 | 1.23 |
[13C, 15N]Histidine, 3TBDMS | ME516632 | 0.01 | 1.38 | 1.25 | 1.32 | 0.02 | 1.79 | 0.52 | 1.23 | 0.01 | 1.36 | 1.23 | 1.28 | 0.02 | 1.58 | 1.47 | 1.52 |
[13C, 15N]Aspartic acid, 3TBDMS | ME516629 | 0.01 | 1.42 | 1.34 | 1.37 | 0.02 | 1.69 | 0.65 | 1.03 | 0.02 | 1.51 | 1.42 | 1.45 | 0.01 | 1.38 | 1.32 | 1.35 |
[13C, 15N]Leucine, 2TBDMS | ME516634 | 0.01 | 1.41 | 1.30 | 1.37 | 0.02 | 1.92 | 0.66 | 1.26 | 0.01 | 1.40 | 1.34 | 1.36 | 0.01 | 1.36 | 1.24 | 1.32 |
[13C, 15N]Serine, 3TBDMS | ME516639 | 0.01 | 1.39 | 1.27 | 1.33 | 0.01 | 1.46 | 1.04 | 1.23 | 0.01 | 1.47 | 1.27 | 1.39 | 0.01 | 1.40 | 1.32 | 1.35 |
[13C, 15N]Alanine, 2TBDMS | ME516628 | 0.01 | 1.36 | 1.18 | 1.28 | 0.02 | 1.74 | 1.29 | 1.50 | 0.01 | 1.46 | 1.24 | 1.35 | 0.01 | 1.27 | 1.10 | 1.19 |
[13C, 15N]Lysine, 3TBDMS | ME516635 | 0.01 | 1.44 | 1.21 | 1.28 | 0.02 | 1.85 | 0.90 | 1.52 | 0.01 | 1.40 | 1.23 | 1.31 | 0.01 | 1.36 | 1.19 | 1.27 |
[13C, 15N]Threonine, 3TBDMS | ME516640 | 0.01 | 1.39 | 1.14 | 1.28 | 0.02 | 2.01 | 0.97 | 1.32 | 0.01 | 1.47 | 1.19 | 1.33 | 0.01 | 1.40 | 1.18 | 1.27 |
[13C, 15N]Tyrosine, 3TBDMS | ME516641 | 0.01 | 1.34 | 1.13 | 1.27 | 0.02 | 2.08 | 0.93 | 1.40 | 0.01 | 1.37 | 1.21 | 1.30 | 0.01 | 1.39 | 1.23 | 1.29 |
[13C, 15N]Glycine, 2TBDMS | ME516631 | 0.02 | 1.25 | 1.09 | 1.31 | 0.02 | 1.97 | 0.98 | 1.40 | 0.01 | 1.68 | 1.30 | 1.47 | 0.02 | 1.13 | 1.17 | 1.19 |
[13C, 15N]Methionine, 2TBDMS | ME516636 | 0.01 | 1.28 | 1.22 | 1.24 | 0.02 | 1.92 | 1.09 | 1.30 | 0.02 | 1.52 | 1.31 | 1.42 | 0.01 | 1.24 | 1.19 | 1.20 |
[13C]Succinate | ME516647 | NA | 0.82 | 0.98 | 0.89 | NA | 0.97 | 1.63 | 1.29 | NA | 0.81 | 1.05 | 0.91 | NA | 0.76 | 1.00 | 0.89 |
[13C]Fumatate | ME516645 | NA | 0.89 | 0.99 | 0.96 | NA | 0.98 | 1.46 | 1.21 | NA | 0.85 | 0.96 | 0.90 | NA | 0.90 | 0.97 | 0.93 |
[13C]Malate | ME516646 | NA | 0.86 | 0.98 | 0.94 | NA | 1.09 | 1.53 | 1.18 | NA | 0.88 | 0.99 | 0.93 | NA | 0.77 | 0.98 | 0.89 |
[13C]Alpha_Ketoglutarate | ME516643 | NA | 0.64 | 0.75 | 0.69 | NA | 0.98 | 2.72 | 1.56 | NA | 0.66 | 0.85 | 0.77 | NA | 0.67 | 0.92 | 0.80 |
[13C]Citrate | ME516644 | NA | 0.66 | 0.88 | 0.77 | NA | 0.84 | 2.90 | 1.68 | NA | 0.66 | 0.78 | 0.73 | NA | 0.56 | 0.83 | 0.71 |
Factors:
F1 | Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D). |
F2 | Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F3 | Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F4 | Source_Name[gating]:Lineage-negative (Lin–) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F5 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D). |
F6 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). |
F7 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). |
F8 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C, Fig2.D). |
F9 | Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D). |
F10 | Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F11 | Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F12 | Source_Name[gating]:Lin– Scal1+ c-Kit+ (LSK) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F13 | Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 1 h | Batch:1a | Note:[13C, 15N] AAs were used for AA uptake (Fig1.B); unlabeled AAs were used for total AA (Fig1.A) and TCA substrate levels (Fig1.D). |
F14 | Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F15 | Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |
F16 | Source_Name[gating]:Mature hematopoietic cells (Lin+ cells) | Treatment:[13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1b | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig1.C). |